Aprotinin to Improve Cerebral Outcome after Hypothermic Circulatory Arrest: A Study in a Surviving Porcine Model
DOI:
https://doi.org/10.1532/HSF98.20061007Abstract
Background. Aprotinin is a serine protease inhibitor, which is usually used during cardiac surgery to reduce blood loss. There is evidence that aprotinin has neuroprotective effects during ischemia. We planned this study to evaluate its potential neuroprotective efficacy during hypothermic circulatory arrest (HCA).
Methods. Twenty piglets with a median weight of 25.7 kg (interquartile range, 23.9-26.6) were randomly assigned to receive aprotinin or placebo prior to a 75-minute period of HCA at 18°C. Brain microdialysis parameters and neurological and histological scores were the primary outcome measures.
Results. Changes in brain metabolic parameters and histopathological findings were favorable in the aprotinin group. Brain lactate concentrations were significantly lower in the aprotinin group during the experiment (P = .02) along with blood lactate concentrations in the aprotinin group (P = .023). Brain glucose was significantly higher during the experiment (P = 0.02). Intracranial pressure tended to be higher in the control group. Two of 10 animals in the aprotinin group and 4 of 10 in the control group failed to reach full recovery on the seventh postoperative day. Four animals of 10 in the aprotinin group and 6 animals of 10 in the control group had brain infarction (P = .40).
Conclusions. The present data suggest that aprotinin mitigates cerebral damage and improves neurological outcome following a period of HCA.
References
Alonso A, Witten CW, Hill GE. 2000. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced inflammation in humans. Ann Thorac Surg 67:392-5.nAsimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. 2000. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 69:1192-7.nFrumento RJ, O'Malley CMN, Bennett-Guerrero E. 2003. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 75:479-84.nGillespie EL, Gryskiewicz KA, White M, et al. 2005. Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. Am J Health-Syst Pharm 62:1370-4.nJean WC, Spellman SR, Nussbaum ES, Low WC. 1998. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 43:1382-96.nHill GE, Alonso A, Spurzeman JR, Stammers AH, Robbins RA. 1995. Aprotinin and methyleprednisolone equally blunt neutrophil cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-62.nIvert T, Intonti M, Stain-Malmgren R, Dumitrescu A, Blomback M. 1998. Effects of aprotinin during cardiopulmonary bypass in patients treated with acetylsalicylic acid. Scand Cardiovasc J 32:289-95.nKamiya T, Katayama Y, Kashiwagi F, Terashi A. 1993. The role of bradykinin in mediating ischemic brain edema in rats. Stroke 24:571-5.nNicole O, Dogagne F, Ali C, et al. 2001. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signalling. Nature 7:59-64.nPokela M, Biancari F, Rimpiläinen J, et al. 2001. The role of cerebral microdialysis in predicting the outcome after experimental hypothermic circulatory arrest. Scand Cardiovasc J 35:395-402.nRoyston D, Bidstrup BP, Taylor KM, Sapsford RN. 1987. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 5:1289-91.nVan Oeveren W, Jansen NJ, Bibtrup BP, et al. 1987. Effects of aprotinin an hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44:640-5.nVan Oeveren W, Harder MP, Roozendal KJ, Eijsman L, Wiidevuur CRH. 1990. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788-97.nWeiss SJ. 1989. Tissue destruction by neutrophils. N Engl J Med 320:365-76.nKhan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW. 2005. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 79:1545-50.nLord RA, Roath OS, Thompson JF, Chant AD, Francis JL. 1992. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg 79:517-21.nSedrakyan A, Treasure T, Elefteriades JA. 2004. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128:442-8.nTsirka SE, Gualandris A, Amaral DG, Stricland S. 1995. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue-plasminogen activator. Nat Med 377:340-4.n
